Chargement en cours...
Dapagliflozin: A Review in Type 1 Diabetes
Oral dapagliflozin (Edistride(®), Forxiga(®)) is approved in the EU at a dosage of 5 mg/day as an adjunct to insulin in adults with type 1 diabetes (T1D) and a body mass index (BMI) of ≥ 27 kg/m(2), when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. As a...
Enregistré dans:
| Publié dans: | Drugs |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6881422/ https://ncbi.nlm.nih.gov/pubmed/31664708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01213-x |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|